CHRNA7 and cancer: In contrast to the α7-nAChR-mediated stimulatory effects on cancer growth, heteromeric α4β2-nAChR seems to be one of the major inhibitors of cancer development and progression through its release of GABA, which blocks the cancer-stimulating effects of β-adrenergic receptors by inhibiting cAMP [18].